Skip to content

Europe CIS

Europe CIS provides a broad range of Sterile Focus and Regional Brands and undertakes third-party manufacturing. The revenue contribution from the Sterile Focus Brands portfolio is the second highest after Asia, and consists of Anaesthetics and to a lesser extent Thrombosis products in Russia and the Europe CIS region. The manufacturing operations, which span across both active pharmaceutical ingredients (“APIs”) and FDF production, are widely accredited and provide a variety of technologies for Aspen’s own commercialisation strategy and for third-party use.

Key Countries

France
Germany
Ireland
Netherlands
Russian Federation

KEY BRANDS

Brand Therapeutic category
Emla Local anaesthetic
Fraxiparine Low molecular weight heparin
Ovestin Estrogen hormone replacement
Ultiva Injectable general anaesthetic
Xylocaine Regional anaesthetic

NUMBER OF PERMANENT EMPLOYEES

2 192

June 2022

2 195

June 2021

europe-cis

STATISTICS

Number of products launched:

Nil

(2021: 1)

Number of product recalls:

5

(2021: 2)

Average staff turnover:

9%

(2020: 11%)

Number of work-related fatalities:

Nil

(2021: Nil)

Sales representatives:

140

(2021: 149)

Revenue 2021
R’million
2020 (CER)
R’million
Change
%
Commercial Pharmaceuticals 4 737 4 931 (4)
Regional Brands 1 594 1 582 1
Sterile Focus Brands 3 143 3 349 (6)
Manufacturing 8 368 7 783 8
FDF 3 175 2 104 51
API Biochem 778 1 161 (33)
API Chemicals 4 415 4 518 (2)
Total 13 105 12 714 3

Note: Commercial Pharmaceuticals revenue is by customer geography and Manufacturing revenue is by place of manufacture.

Scroll To Top